Two House committees today marked up revised versions of the Lower Prescription Drug Costs Now Act (H.R. 3) — legislation that would make a series of changes to the Medicare program in an effort to lower the price of prescription drugs.
The suicide rate jumped 56% for Americans aged 10 to 24 between 2007 and 2017, and the homicide rate jumped 18% between 2014 and 2017 for the same population.
Near universal health care coverage could be achieved without a complete overhaul of the health system, according to a report released today by the Urban Institute and the Commonwealth Fund.
Congress should pass legislation that protects patients from surprise medical bills and rejects rate setting, hospital leaders said today at an AHA briefing on Capitol Hill.
The AHA and six other organizations today submitted comments to the Drug Enforcement Administration on its proposed rule regarding controlled substances quotas.
The Food and Drug Administration last week authorized marketing of a rapid diagnostic test to detect Ebola virus antigens in human blood from certain living individuals as well as samples from those recently deceased who are suspected to have died from Ebola.
The AHA is accepting nominations through Nov. 25 for its 2020 Dick Davidson NOVA Award, which recognizes outstanding collaboration by hospitals and health systems for healthier communities.
A federal judge in Washington state today blocked nationwide a Department of Homeland Security final rule from taking effect that would limit the ability of legal immigrants to adjust or extend their immigration status or gain full citizenship based on their prospective receipt of public benefits.
The Centers for Disease Control and Prevention today released updated interim clinical guidance for U.S. health care providers evaluating and caring for patients with lung injury associated with use of electronic cigarette or vaping products.
The AHA today urged the Drug Enforcement Administration to explicitly consider drug shortages when setting and adjusting aggregate production quotas, citing concern that the agency’s proposal to reduce 2020 production quotas for five opioid controlled substances would exacerbate shortages of injectable opioid medications.